From 1984 to 1996, 31 consecutive children without sibling donors, aged 5-19 years (median 8) with acute lymphoblastic leukaemia (ALL) in second complete remission (CR), received unpurged autologous bone marrow transplantation (ABMT) after melphalan and single fraction total body irradiation (TBI). ABMT was performed using fresh unmanipulated marrow harvested after standard reinduction and consolidation therapy 2-11 months (median 5) after relapse. With a median survival of 2.9 years the probability of survival for all patients in continuing second CR was 45.1% (95% CI, 24%-62%) after 5 years. Regimen-related and non-leukaemia mortality was 7% (95% CI, 2%-26%). The longest time to second relapse from ABMT was 3.1 years. Pituitary and gonadal dysfunction requiring hormonal replacement therapy occurred in the majority of long-term survivors. Twelve patients developed cataracts. ABMT with melphalan/single fraction TBI has proved an effective anti-leukaemia treatment with low regimen-related mortality but significant long-term morbidity. The current approach of allogeneic BMT from an unrelated donor when no sibling donor is available, following conditioning with cyclophosphamide/ fractionated TBI has resulted in a reduced relapse rate and improved short-term overall survival in the treatment of relapsed childhood ALL. However, long-term results are awaited. Bone Marrow Transplantation (2000) 25, 599-603. Keywords: childhood ALL; autologous BMT; melphalan/TBI; second remission Childhood acute lymphoblastic leukaemia (ALL) is curable in 60-70% of patients in first complete remission (CR) with first-line therapy.
Childhood acute lymphoblastic leukaemia (ALL) is curable in 60-70% of patients in first complete remission (CR) with first-line therapy. 1, 2 However, the outcome of children in second or subsequent CR is much less favourable following second-line therapy with or without bone marrow transplantation (BMT). 3, 4 The two most important factors that affect the long-term prognosis post relapse are the site of relapse (bone marrow vs extramedullary sites) and duration of first remission. 3, 4 Allogeneic BMT from an HLA-matched sib- ling resulted in an improved leukaemia-free survival when compared to chemotherapy, particularly for bone marrow and early extramedullary relapses defined as those occurring within 30 months from initial diagnosis. [5] [6] [7] As only less than 30% of patients have a matched sibling bone marrow donor, other treatment options for the remaining patients include second-line chemotherapy or BMT from an unrelated bone marrow or umbilical cord blood donor, or the patient's own bone marrow or peripheral blood stem cells. Randomised trials comparing autologous BMT (ABMT) with other treatment modalities are lacking. Analysis of comparative studies is difficult because of small numbers, different conditioning regimens and whether or not the marrow was purged. 3, 6, [8] [9] [10] The most commonly used conditioning regimen in children prior to BMT is cyclophosphamide and total body irradiation (TBI).
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Our group previously reported a greater anti-leukaemic effect of melphalan/TBI conditioning over cyclophosphamide/ TBI in allogeneic BMT for patients with acute myeloid leukaemia in first remission. 12 The melphalan/TBI arm was, however, associated with higher toxicity, especially renal failure, which could possibly be attributed to an interaction between melphalan and cyclosporine. Other reports demonstrate that melphalan/TBI conditioning is well tolerated prior to ABMT particularly in children. 13, 14 A previous report 14 described our early results and we now present our single centre long-term experience of ABMT for second remission childhood ALL following conditioning with melphalan and single fraction TBI.
Patients and methods

Patients
Thirty-one patients with ALL in second remission and under the age of 21 years underwent autologous bone marrow transplantation (ABMT) from April 1984 to March 1996. There were 19 males and 12 females. The median age at initial diagnosis of leukaemia was 4 years (range 1.5-18.5) and the median age at transplant was 8 years (range 5-19.6) . At initial diagnosis, the median white blood cell count was 7.2 × 10 9 /l (range 0.9-199). Twenty-four patients had common ALL, five T-ALL and the phenotype was unknown in two. Five patients had only extra-medullary relapse, CNS (n = 3), testes (n = 1), testes and CNS (n = 1) and six patients had combined bone marrow and extra-medullary relapse. Of the 19 patients with early relapse, 10 had isolated bone marrow relapse, four combined bone marrow and CNS relapse, three isolated CNS relapse, one isolated testicular relapse and one had combined CNS and testicular relapse. All patients with isolated extra-medullary relapses belonged to the early relapse group. Second remissions were achieved with different chemotherapy regimens. Median duration of second remission before ABMT was 120 days (range 9-289).
Conditioning regimen
Bone marrow was harvested under general anaesthesia on day −1. This was followed by an intravenous infusion of melphalan at a dose of 140 mg/m 2 , after 4 h of prehydration with 4% dextrose/0.18% saline continued for 18-24 h post melphalan. Single fraction TBI at a median dose of 10.5 Gy was given on day 0. Unpurged and uncryopreserved autologous bone marrow was reinfused on the same day with a median of 2.16 × 10 8 /kg nucleated cells (range 1.06-4.9).
Supportive measures
All patients were kept in isolation rooms with positivepressure ventilation until the absolute neutrophil count exceeded 0.5 × 10 9 /l for 2 consecutive days. Episodes of febrile neutropenia (defined as fever Ͼ38°C and absolute neutrophil count of Ͻ1 × 10 9 /l) were treated with broadspectrum antibiotics according to local policy and microbiology results. Packed red blood cell transfusions were given to maintain a haemoglobin of at least 9 g/dl and platelet transfusions were given whenever the platelet count was Ͻ20 × 10 9 /l. All blood products were irradiated to 20 Gy and CMV negative blood products were given to patients with negative CMV serology. None of the patients were given haemopoietic growth factors. All patients received continuous oral penicillin and trimethoprim-sulphamethaxazole prophylaxis after recovery of neutrophil and platelet counts, according to local policy.
Results
Toxicity
All patients had WHO grade 4 myelotoxicity, grade 2-4 oral mucositis and fever necessitating antibiotic therapy. The median time for onset of fever after transplant was 6 days (range 0-11) and the median duration of fever was 13 days (range 2-43). Empirical systemic antifungal therapy (conventional amphotericin) was administered to 17 patients with persistent fever Ͼ96 h from onset.
Blood cultures were positive in nine cases and Pneumocystis carinii was isolated from bronchial secretions of one patient who ultimately died from the infection. WHO grade 1 renal toxicity was observed in two cases, grade 1 hepatic toxicity was observed in another two, while one patient had grade 4 hepatic toxicity.
There were two deaths from infection in remission; fulminant sepsis (n = 1) and Pneumocystis carinii pneumonia (n = 1).
Engraftment
Thirty patients showed neutrophil recovery defined as a neutrophil count of Ͼ0.5 × 10 9 /l at a median of 30 days (range 15-104). One patient who did not engraft relapsed within 3 months. Platelet engraftment, defined as a sustained unsupported platelet count of Ͼ20 × 10 9 /l, was achieved in 28 patients at a median of 32.5 days (range 12-89). Three patients never achieved platelet recovery, of whom two relapsed and died within 90 days.
Survival
Fifteen patients relapsed post-ABMT in bone marrow (n = 14) and CNS (n = 1). Median time to relapse was 6.5 months. Eleven out of 15 relapses occurred within 12 months of ABMT and the longest time to relapse was 3.14 years. Only one of the relapsed patients is still alive after ayurvedic treatment and is in remission 10 years later. All other relapsed patients have died.
Eight out of the 19 patients with early first relapse are alive and free of disease. Six of these survivors had bone marrow relapse and one each had isolated testicular and CNS relapse.
Median duration of first remission for these eight survivors was 1.93 years (range 0.33 to 2.44) and the median follow-up post ABMT in these patients is 5.1 years (range 0.6-10.4 years). Of the eight patients with bone marrow relapses while on chemotherapy, two are alive in CR at 4.8 and 9.8 years, respectively.
The median survival time (as at January 1999) for all patients is 2.9 years, with a probability of survival of 45.1% (95% CI 24%-62%) after 5 years (Figure 1 ). The overall survival of patients with a first remission duration of less than 2.5 years was not significantly different from those with a remission duration of more than 2.5 years (P = 0.3). Patients with a first remission duration of less than 2 years (n = 12) did significantly worse than those with a remission duration of 2 or more years. The overall survival for the latter two groups was 29.2% and 60.7% at 4 years after ABMT respectively (P = 0.04) (Figure 2 ). Although the number of patients is small, the other significant prognostic factor was time to neutrophil engraftment; those with less than 25 days had a better survival (P = 0.013). On a stepwise multivariate analysis with the Cox proportionate hazard model, using age at the time of ABMT, sex, duration of first remission before ABMT, time to neutrophil and platelet engraftment as variables, only initial remission duration (P = 0.02) and time to neutrophil engraftment (P = 0.005) emerged as statistically significant.
Late effects
The median follow-up period for the 15 survivors is 7.64 years (range 0.56-14.2). Twelve patients are known to have developed cataracts and to have needed surgery. Eight patients have had primary gonadal failure indicated by raised gonadotrophins and subnormal sex steroid concentration. Eight patients have received growth hormone supplements following confirmation by insulin tolerance tests of growth hormone insufficiency and seven long-term thyroxine. Six patients have been treated with growth hormone replacement, thyroxine and sex steroids. Detailed endocrine evaluation was not possible in two pre-pubertal patients and three post pubertal patients.
Discussion
The best treatment for relapsed childhood ALL is still not clear. Increasing the intensity has improved the results to some extent, yet the majority do not fare well. 17 Duration of first remission and site of relapse, bone marrow vs extramedullary sites, are the two most important factors that influence outcome. 3, 4 Patients with bone marrow relapse during the first 48 months and those who relapse at other sites within 30 months from diagnosis have a poorer out- 
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come and decisions regarding treatment should take this into consideration. A bone marrow relapse while on chemotherapy carries the worst prognosis, irrespective of the treatment given, and for such patients new therapeutic modalities are urgently required. 3, 4 There have been no prospective randomised trials to assess the best therapeutic option for children with relapsed ALL. Comparative studies suggest that matched sibling BMT has an advantage over chemotherapy particularly for patients who relapse while still on chemotherapy. [5] [6] [7] As a minority of patients have an HLA-matched sibling, alternative sources of stem cells from an unrelated donor or the patient's own marrow have been used. ABMT is associated with least regimen-related toxicity, no graft-versus-host disease (GVHD) and is available for all patients. Its major disadvantage is the high risk of leukaemic relapse, and this is also influenced by the duration of first remission. 11, 18 We found similar results (P = 0.04), although the number of patients in our study is small. The overall relapse rate for our patient group was 48% (15/31) with more relapses in patients with an initial remission of less than 2.5 years.
Several studies have shown no significant benefit of ABMT over chemotherapy. 3, 8 Matched pair analysis by Parsons et al 9 has shown that the outcome of ABMT is equivalent to allogeneic BMT in relapsed childhood B-lineage ALL with a long first remission and no adverse cytogenetic features if the marrow is in remission at the time of transplant. The causes of treatment failure were different in the two groups. Event-free survival (EFS) after ABMT or allogeneic BMT was also comparable in another study of patients with high risk ALL defined as T cell leukaemia, short first remission with high white cell count at presentation or advanced age in first CR. 10 Another study comparing ABMT to unrelated donor BMT showed no statistically significant overall survival advantage of the latter in children. However, ABMT was associated with a higher relapse rate and a lower regimenrelated mortality. 19 A recent report on the role of ABMT in second remission ALL showed that the EFS was significantly better in patients with isolated extra-medullary relapse. 20 It was suggested that ABMT represents a valuable therapeutic option for patients with no matched sibling in second remission after an isolated CNS relapse. 21 Different conditioning regimens have been used prior to BMT in an attempt to reduce leukaemic relapse without increasing toxicity from BMT. 11 Melphalan and TBI have been used in this institution as a conditioning regimen for more than a decade instead of the more commonly used regimen of cyclophosphamide and TBI. TBI was given as a single fraction in this study because of a potentially better anti-leukaemia effect. A comparison of these two regimens in adults and children with relapsed AML has shown that the former regimen had a better anti-leukaemia activity, but more toxic deaths. 12 In our study the transplant-related mortality (TRM) was 6.5% which is comparable to other studies. 10 Sutton et al 22 found that the mode of delivery of TBI has an independent predictive factor for TRM, with a higher incidence of fatal interstitial pneumonia in patients treated with single fraction TBI, a finding not confirmed in another study. 23 However, there was no difference in the overall leukaemia-free survival because of a lower relapse rate in the single fraction group.
Another study in patients with acute leukaemia conditioned with a TBI-based regimen showed that TRM is lower in patients treated after 1985 and that this was not significantly influenced by the TBI technique. 24 However, thyroid hypofunction was more common in patients who received single fraction TBI, 11, 24 similar to the findings in this study. Height was significantly more impaired 3 years after TBI in a single fraction group despite the lower total dose of radiation. 25 The incidence of thyroid dysfunction, both overt hypothyroidism and TSH abnormalities was lower with a fractionated schedule of TBI. 26 We conclude that ABMT offers an alternative therapeutic modality in children with ALL in second remission particularly for those with a long first remission. The availability of unrelated donor BMT and its comparable regimenrelated mortality to that of sibling BMT 27, 28 has largely reduced the use of ABMT, particularly in children with early relapse, because of the hope of exploiting a graftversus-leukaemia effect. Melphalan/single fraction TBI has now been replaced in our hospital by unrelated donor BMT following cyclophosphamide/fractionated TBI for the treatment of relapsed childhood ALL. The long-term results of UD-BMT are awaited.
